Nightstar Therapeutics PLC (NITE) Expected to Earn FY2021 Earnings of ($1.18) Per Share

Nightstar Therapeutics PLC (NASDAQ:NITE) – Equities research analysts at Wedbush dropped their FY2021 earnings per share (EPS) estimates for shares of Nightstar Therapeutics in a research report issued on Tuesday. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($1.18) for the year, down from their prior estimate of ($1.08). Wedbush has a “Outperform” rating and a $31.00 price target on the stock.

A number of other equities analysts have also recently commented on the company. Leerink Swann initiated coverage on Nightstar Therapeutics in a report on Monday, October 23rd. They set an “outperform” rating and a $25.00 price target for the company. Chardan Capital initiated coverage on Nightstar Therapeutics in a report on Wednesday, January 3rd. They set a “buy” rating and a $40.00 price target for the company. BMO Capital Markets initiated coverage on Nightstar Therapeutics in a report on Monday, October 23rd. They set an “outperform” rating and a $30.00 price target for the company. Finally, Jefferies Group initiated coverage on Nightstar Therapeutics in a report on Monday, October 23rd. They set a “buy” rating and a $25.00 price target for the company. Five analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $30.20.

Nightstar Therapeutics (NITE) opened at $14.38 on Friday. Nightstar Therapeutics has a fifty-two week low of $11.99 and a fifty-two week high of $24.93. The company has a market capitalization of $418.88 and a price-to-earnings ratio of -28.76.

A number of institutional investors and hedge funds have recently modified their holdings of NITE. Citadel Advisors LLC acquired a new position in Nightstar Therapeutics in the 3rd quarter worth about $240,000. Nationwide Fund Advisors acquired a new position in Nightstar Therapeutics in the 3rd quarter worth about $1,196,000. Sphera Funds Management LTD. acquired a new position in Nightstar Therapeutics in the 3rd quarter worth about $1,728,000. Alyeska Investment Group L.P. acquired a new position in Nightstar Therapeutics in the 3rd quarter worth about $1,920,000. Finally, Chartwell Investment Partners LLC acquired a new position in Nightstar Therapeutics in the 3rd quarter worth about $3,995,000. 27.12% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3148571/nightstar-therapeutics-plc-nite-expected-to-earn-fy2021-earnings-of-1-18-per-share.html.

Nightstar Therapeutics Company Profile

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.